JB Capital’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.6M Buy
12,310
+460
+4% +$151K 0.15% 85
2025
Q4
$4.15M Sell
11,850
-255
-2% -$86.2K 0.17% 60
2025
Q3
$3.91M Buy
12,105
+2,438
+25% +$758K 0.17% 68
2025
Q2
$3.76M Sell
9,667
-12
-0.1% -$4.83K 0.18% 64
2025
Q1
$4.21M Buy
9,679
+295
+3% +$118K 0.23% 51
2024
Q4
$3.46M Buy
9,384
+8,038
+597% +$3.36M 0.19% 58
2024
Q3
$700K Buy
1,346
+220
+20% +$118K 0.04% 132
2024
Q2
$610K Buy
1,126
+6
+0.5% +$3.17K 0.04% 136
2024
Q1
$581K Sell
1,120
-75
-6% -$37.3K 0.04% 129
2023
Q4
$564K Buy
1,195
+96
+9% +$44.4K 0.04% 125
2023
Q3
$479K Hold
1,099
0.04% 120
2023
Q2
$488K Hold
1,099
0.04% 110
2023
Q1
$505K Hold
1,099
0.05% 107
2022
Q4
$564K Sell
1,099
-107
-9% -$54.3K 0.06% 97
2022
Q3
$548K Hold
1,206
0.06% 95
2022
Q2
$582K Buy
1,206
+504
+72% +$249K 0.06% 144
2022
Q1
$345K Buy
702
+2
+0.3% +$914 0.03% 187
2021
Q4
$325K Hold
700
0.03% 202
2021
Q3
$261K Buy
+700
New +$266K 0.03% 261

Other funds holding ELV

JB Capital's ELV Position: Q1 2026 in Review

JB Capital increased its Elevance Health (ELV) stake by 3.9% in Q1 2026, buying an estimated $151K and bringing the position to 12,310 shares worth $3.6M. The position accounts for 0.15% of the portfolio, ranked #85.

JB Capital first reported a position in ELV in Q3 2021 and has held it in 19 quarters since. The position peaked at $4.21M in Q1 2025. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • JB Capital held 12,310 shares of Elevance Health worth $3.6M as of Q1 2026.
  • JB Capital bought 460 Elevance Health shares in Q1 2026, an estimated $151K.
  • Elevance Health made up 0.15% of JB Capital's portfolio in Q1 2026, its #85 holding.
  • JB Capital first reported a position in Elevance Health in Q3 2021 and has held it in 19 quarters since.
  • JB Capital's Elevance Health position peaked at $4.21M in Q1 2025.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on JB Capital's 13F filing for Q1 2026, filed 27 Apr 2026.